FLUOXETINE
- 158. Power-Smith P: Beneficial sexual
side-effects from fluoxetine. Br J Psychiatry 1994; 164:249-250.
- 159. Price JS, Waller PC, Wood SM et al:
A comparison of the post-marketing safety of four selective serotonin
re-uptake inhibitors including the investigation of symptoms occurring
on withdrawal. Br J
Clin Pharmacol 1996; 42:757-763.
- 160. Product Information Ativan(R),
1999, Wyeth-Ayerst Co, Philadelphia, PA
- 161. Product Information: Ativan(R),
lorazepam. Wyeth, Philadelphia, PA, 1991.
- 162. Product Information: Prozac(R),
fluoxetine. Dista Products Company, Indianapolis, IN, 1988.
- 163. Product Information: Prozac(R),
fluoxetine. Dista Products Company, Indianapolis, IN, 1995.
- 164. Product Information: Prozac(R),
fluoxetine. Eli Lilly & Company, Indianapolis, IN, 1990.
- 165. Product Information: Prozac(R),
fluoxetine. Eli Lilly & Company, Indianapolis, IN, 1999.
- 166. Rault S, Grosieux-Dauger C, Verraes
S et al: Bullous pemphigoid induced by fluoxetine (letter). Br J
Derm 1999; 141:755-756
- 167. Riddle MA, Brown N, Dzubinski D et
al: Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc
Psychiatr 1989; 28:587-588.
- 168. Roberge RJ & Martin TG: Mixed
fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med 1994;
23:586-590.
- 169. Roettger JR: The importance of
blood collection site for the determination of basic drugs: a case with
fluoxetine and diphenhydramine overdose (Letter). J Anal Toxicol 1990;
14:191-192.
- 170. Rohrig TP & Prouty RW:
Fluoxetine overdose: a case report. J Anal Toxicol 1989; 13:305-307.
- 171. Roth A, Akyol S & Nelson JC:
Delirium associated with the combination of a neuroleptic, an SSRI, and
benztropine. J Clin
Psychiatry 1994; 55:492-495.
- 172. Rothschild AJ & Locke CA:
Reexposure to fluoxetine after serious suicide attempts by three
patients: the role of akathisia. J Clin Psychiatry 1991; 52:491-493.
- 173. Rothschild AJ: Selective serotonin
reuptake inhibitor-induced sexual dysfunction - efficacy of a drug
holiday. Am J Psychiatry 1995; 152:1514-1516.
- 174. Ruiz: Fluoxetine and the serotonin
syndrome. Ann Emerg Med 1994; 24:983-985.
- 175. Saletu B & Grunberger T:
Classification and determination of cerebral bioavailability of
fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry 1985; 46:45-52.
- 176. Scheepers BDM & Rogers DG:
Dyskinesias following treatment with 5-HT re-uptake inhibitors. J Psychopharmacol
1994; 8:258-260.
- 177. Schenker S, Bergstrom RF, Wolen RL
et al: Fluoxetine disposition and elimination in cirrhosis. Clin
Pharmacol Ther 1988; 44:353-359.
- 178. Scott R, Besag FMC, Neville BGR:
Buccal midazolam and rectal diazepam for treatment of prolonged seizures
in childhood and adolescence: a randomized trial. Lancet 1999;
353:623-626.
- 179. Settle EC Jr & Settle GP: A
case of mania associated with fluoxetine. Am J Psychiatry 1984;
141:280-281.
- 180. Shad MU, Harvey AT & Lucot JB:
A possible pharmacokinetic interaction between fluoxetine and
acetylsalicylic acid (letter). J Clin Psychiatr 1997; 58:549-550.
- 181. Silverglat MJ: Fluoxetine and
sexual dysfunction (letter). JAMA 1995; 273:1489.
- 182. Smith DK & Wenegrat BG: A case
report of serotonin syndrome associated with combined nefazodone and
fluoxetine (letter). J
Clin Psychiatry 2000; 61:146.
- 183. Smith DM & Levitte SS:
Association of fluoxetine and return of sexual potency in three elderly
men. J Clin Psychiatry
1993; 54:317-319.
- 184. Spencer MJ: Fluoxetine
hydrochloride (Prozac) toxicity in a neonate (Letter). Pediatrics 1993;
92:721-722.
- 185. Spier SA & Frontera MA:
Unexpected deaths in depressed medical inpatients treated with
fluoxetine. J Clin
Psychiatry 1991; 52:377-382.
- 186. Spiller HA, Morse S, & Muir C:
Fluoxetine ingestion: a one year retrospective study. Vet Human Toxicol
1990; 32:153-155.
- 187. Stanford MS & Patton JH: In
utero exposure to fluoxetine HCL increased hematoma frequency at birth. Pharmacol
Biochem Behav 1993; 45:959-962.
- 188. Stark P & Hardison CD: A review
of multicenter controlled studies of fluoxetine vs imipramine and
placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 46:53-58.
- 189. Stark P, Fuller RW & Wong DT:
The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985; 46:7-13.
- 190. Steiner W & Fontaine R: Toxic
reaction following the combined administration of fluoxetine and
L-tryptophan: five case reports. Biol Psychiatry 1986; 21:1067-1071.
- 191. Sternbach H: Danger of MAOI therapy
after fluoxetine withdrawal (Letter). Lancet 1988; 11:850-851.
- 192. Sternbach H: The serotonin
syndrome. Am J Psychiatr 1992; 149:1410-1411.
- 193. Sternbach H: The serotonin
syndrome. Am J Psychiatry 1991; 148:705-713.
- 194. Stoll AL, Cole JO & Lukas SE: A
case of mania as a result of fluoxetine-marijuana interaction (Letter). J Clin Psychiatry 1991; 52:280-281.
- 195. Stoll AL, Pope HG & McElroy SL:
High-dose fluoxetine: safety and efficacy in 27 cases (Letter). J Clin Psychopharmacol 1991a;
11:225-226.
- 196. Taddio A, Ito S & Koren G:
Excretion of fluoxetine and its metabolite in human breast milk. Pediatr
Res 1994; 35:1A-443A.
- 197. Taddio A, Ito S & Koren G:
Excretion of fluoxetine and its metabolite, norfluoxetine, in human
breast milk. J Clin
Pharmacol 1996; 36:42-47.
- 198. Technical Information: Eli Lilly,
Inc, 1987.
- 199. Tinsley JA, Olsen MW, Laroche RR et
al: Fluoxetine abuse. Mayo Clin Proc 1994; 69:166-168.
- 200. USP DI Volume I Drug information
for the health care professional. 20th edition, 2000; Micromedex Inc,
World Color Book Services, Taunton, MA.
- 201. Vale JA: Position Statement: gastric
lavage. American
Academy of Clinical Toxicology/European Association of Poisons Centres
and Clinical Toxicologists. Clin Toxicol 1997; 35:711-719.
- 202. Varriale P: Fluoxetine (Prozac) as
a cause of QT prolongation. Arch Int Med 2001; 161:612.
- 203. von Ammon Cavanaugh A: Drug-drug
interactions of fluoxetine with tricyclics. Psychosomatics 1990;
31:273-276.
- 204. Vorhees CV, Acuff-Smith KD,
Schilling MA et al: A developmental neurotoxicity evaluation of the
effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol
1994; 23(2):194-205.
- 205. Weber JJ: Seizure activity
associated with fluoxetine therapy. Clin Pharm 1989; 8:296-298.
- 206. Wernicke JF: The side effect
profile and safety of fluoxetine. J Clin Psychiatry 1985; 46:29-67.
- 207. Wong SHY, Dellafera SS &
Fernandes R: Determination of fluoxetine and norfluoxetine by
high-performance liquid chromatography. J Chromatogr 1990; 499:601-608.
- 208. Zajecka J, Tracy KA & Mitchell
S: Discontinuation symptoms after treatment with serotonin reuptake
inhibitors: a literature review. J Clin Psychiatry 1997; 58:291-297.
- 13.0 AUTHOR INFORMATION
- 13.1 CONTRIBUTOR(S) TO THIS
DOCUMENT
- A. Original publication: 11/85
- B. Most recent revision: 04/01
- C. List of contributors:
§
1.
Katherine M Hurlbut, MD
§
2.
Laurel Praunk, MD
§
3.
Barry H Rumack, MD
§
4.
POISINDEX(R) Editorial Staff
- D. Specialty Board: CNS DRUGS
- Refer to the POISINDEX EDITORIAL BOARD
section for more information. (MG0511)
End of Document